Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Depreciation & Amortization (CF) (2016 - 2025)

Iradimed (IRMD) has disclosed Depreciation & Amortization (CF) for 13 consecutive years, with $380680.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 95.01% to $380680.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, up 42.54% year-over-year, with the annual reading at $1.2 million for FY2025, 42.54% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $380680.0 at Iradimed, down from $383722.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $494176.0 in Q2 2022, with the low at -$692905.0 in Q4 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $241333.8, with a median of $216782.5 recorded in 2024.
  • The sharpest move saw Depreciation & Amortization (CF) tumbled 279.23% in 2022, then soared 129.64% in 2023.
  • Over 5 years, Depreciation & Amortization (CF) stood at $386600.0 in 2021, then crashed by 279.23% to -$692905.0 in 2022, then skyrocketed by 129.64% to $205375.0 in 2023, then decreased by 4.95% to $195210.0 in 2024, then skyrocketed by 95.01% to $380680.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $380680.0, $383722.0, and $207476.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.